Prospects for the use of NK cells in immunotherapy of human cancer

被引:438
作者
Ljunggren, Hans-Gustaf [1 ]
Malmberg, Karl-Johan [1 ]
机构
[1] Huddinge Univ Hosp, Karolinska Inst, Dept Med, Ctr Infect Med, S-14186 Huddinge, Sweden
关键词
D O I
10.1038/nri2073
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Current insights into the molecular specificities that regulate natural killer (NK)-cell function suggest that it might be possible to design NK-cell-based immunotherapeutic strategies against human cancer. Here, we describe evidence for NK-cell targeting of human tumours and address crucial questions that, in our opinion, require consideration for the development of successful NK-cell-based therapies. Appropriately used, we predict that NK cells will have a role, both directly and in combination with other treatment modalities, in future treatment of cancer.
引用
收藏
页码:329 / 339
页数:11
相关论文
共 145 条
[81]   Cellular immunotherapy after allogeneic stem cell transplantation in hematologic malignancies [J].
Kolb, HJ ;
Simoes, B ;
Schmid, C .
CURRENT OPINION IN ONCOLOGY, 2004, 16 (02) :167-173
[82]   DONOR LEUKOCYTE TRANSFUSIONS FOR TREATMENT OF RECURRENT CHRONIC MYELOGENOUS LEUKEMIA IN MARROW TRANSPLANT PATIENTS [J].
KOLB, HJ ;
MITTERMULLER, J ;
CLEMM, C ;
HOLLER, E ;
LEDDEROSE, G ;
BREHM, G ;
HEIM, M ;
WILMANNS, W .
BLOOD, 1990, 76 (12) :2462-2465
[83]   NK cell recognition [J].
Lanier, LL .
ANNUAL REVIEW OF IMMUNOLOGY, 2005, 23 :225-274
[84]  
Latchman Y, 1998, J IMMUNOL, V161, P5809
[85]  
LAW TM, 1995, CANCER-AM CANCER SOC, V76, P824, DOI 10.1002/1097-0142(19950901)76:5<824::AID-CNCR2820760517>3.0.CO
[86]  
2-N
[87]   Engagement of CD160 receptor by HLA-C is a triggering mechanism used by circulating natural killer (NK) cells to mediate cytotoxicity [J].
Le Bouteiller, P ;
Barakonyi, A ;
Giustiniani, J ;
Lenfant, F ;
Marie-Cardine, A ;
Aguerre-Girr, M ;
Rabot, M ;
Hilgert, I ;
Mami-Chouaib, F ;
Tabiasco, J ;
Boumsell, L ;
Bensussan, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (26) :16963-16968
[88]   Determinants of antileukemia effects of allogeneic NK cells [J].
Leung, W ;
Iyengar, R ;
Turner, V ;
Lang, P ;
Bader, P ;
Conn, P ;
Niethammer, D ;
Handgretinger, R .
JOURNAL OF IMMUNOLOGY, 2004, 172 (01) :644-650
[89]   Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma [J].
Link, Brian K. ;
Ballas, Zuhair K. ;
Weisdorf, Daniel ;
Wooldridge, James E. ;
Bossler, Aaron D. ;
Shannon, Mary ;
Rasmussen, Wendy L. ;
Krieg, Arthur M. ;
Weiner, George J. .
JOURNAL OF IMMUNOTHERAPY, 2006, 29 (05) :558-568
[90]   HOST-RESISTANCE DIRECTED SELECTIVELY AGAINST H-2-DEFICIENT LYMPHOMA VARIANTS - ANALYSIS OF THE MECHANISM [J].
LJUNGGREN, HG ;
KARRE, K .
JOURNAL OF EXPERIMENTAL MEDICINE, 1985, 162 (06) :1745-1759